Amgen Expands in North Carolina with $1 Billion Biomanufacturing Facility
Investment:
Amgen is investing $1 billion in a new biomanufacturing facility in North Carolina, deepening its roots in the state3.
Location:
The facility is part of a broader trend of pharmaceutical companies expanding their manufacturing capabilities in North Carolina, which has become a hub for biotechnology and pharmaceutical production.
Industry Context:
This investment follows similar moves by other pharmaceutical companies, such as Johnson & Johnson, which recently announced a $2 billion investment in a biologics manufacturing facility in Wilson, NC1.
Economic Impact:
The new facility is expected to create jobs and contribute to the local economy, further establishing North Carolina as a key location for biopharmaceutical manufacturing.
Strategic Importance:
The expansion underscores Amgen's commitment to increasing its manufacturing capacity to meet growing demand for biologic therapies, particularly in oncology and other critical therapeutic areas.
Sources:
1. https://endpts.com/jj-budgets-over-2b-for-new-north-carolina-biologics-facility/